Also available as PDF (figures and tables appear in the PDF).
Background: Reward Deficiency Syndrome (RDS) is a hypo-dopaminergic state that predisposes to obsessive-compulsive behaviors. Obesity is part of RDS since the individual is predisposed to reward-driven eating behavior that leads to overeating. The allele A1 of the SNP C32806T in Dopamine D2 receptor gene (DRD2) is associated with reduction of DRD2 levels and higher BMI in adults. DRD2 are expressed in beta cells and modulate insulin secretion. The aim of this study is to investigate the relation between this SNP and obesity and metabolic alterations in children. Methods: Fifty five obese children and 50 healthy controls were analyzed for DRD2 Taq1A polymorphism Genotyping was performed by polymerase chain reaction and restriction fragment length polymorphism. Glucose, insulin and lipid profile were measured. The Homeostatic model assessment (HOMA) was calculated. Results: We found three genotypes: A1A1(12,4%), A1A2(33,3%) and A2A2(54,3%). The A1 allele was more present in: obese than in euthrophic (34,5%*23%), in children with altered HOMA ß (38,2% * 24,6%), children with altered Total Cholesterol (35,2%*19,5%) and lower levels of triglycerides. Children were divided in 4 subgroups in accordance to the function of pancreatic beta cells and BMI-Z; subgroups with normal secreting pancreatic beta cell demonstrated significant difference for allelic and genotypic distribution, with lower presence of A1A1 and A1A2 genotypes and higher presence of A2 allele. Conclusions: Besides confirming the association with childhood obesity, our results show for the first time that: A1 allele is associated with TC≥170 mg/dl, lower TG levels and HOMA ß ≥175. A2 allele is associated with normal HOMA ß, being a protective factor for pancreatic secretion. The recognition of predisposed individuals through determinations of risks polymorphisms can lead to new paths for treatment and prevention of metabolic abnormalities.
Keywords: Childhood obesity; DRD2 gene; HOMA; Dopamine; Genetic polymorphism; Childhood obesity; DRD2 gene; HOMA; Dopamine; Genetic polymorphism
Exogenous obesity is a complex disease of multifactorial etiology in which pleiotropic genetic syndromes and monogenic diseases account for only 1% of cases. It is recognized by World Health Organization (WHO) as one of the ten most important health problems in many societies.1 The prevalence of obesity has grown worldwide, being endemic in several developed and transition countries, and it is an important cause of morbidity and mortality in the developing world. A report published in January 2014 conducted by the Overseas Development Institute in Britain shows a general picture of the evolution of the obesity in the world in the last 30 years. Adult overweight is observed in 70% of North American’s, and in 63% of Latin American’s, a significant increase compared to 30% observed in the 80’s.3
About 60% of obese children, aged 5-10 years have at least one risk factor for cardiovascular disease (hypertension, dyslipidemia, hyperinsulinemia, impaired glucose metabolism, thrombotic risk factors) and 20% of these children have two or more of these factors.4 In addition to metabolic complications, the obese children and adolescents also have higher incidence of asthma, sleep apnea, polycystic ovary syndrome, and psychosocial complications.5
Studies show that heredity is an important factor for 6,7 childhood-onset obesity.6,7 The largest study concerning the genetics of childhood obesity, where 5530 cases and 8318 controls were evaluated, showed a strong genetic influence in the development of childhood obesity.8
The dopamine type-2 receptor (DRD2) gene contains 66.097 pb, it is located on chromosome 11 (q22-q23) and encodes the D2 subtype of the dopamine receptor, a transmembrane protein that couple to G-protein and inhibits adenylyl cyclase activity. This gene was included in HOGM (Human Obesity Gene Map) supported by 5 studies of candidate genes, but none of these studies had included children’s evaluation.9
The DRD2 gene is highly polymorphic, and therefore, there are several SNPs described for it. The C32806T SNP, a C-T substitution located in a noncoding region of the DRD2 locus, affects the availability of the D2 receptor. The A1 allele (T) has been associated with reduced glucose metabolic rate in dopaminergic human brain regions.10 Variations on dopaminergic receptors and in dopamine release are involved with overeating and obesity. When exposed to high-fat diet, mice with decreased levels of DRD2 gain more weight than mice with normal levels.11 Studies have suggested that obese may have a decreased mass are associated with DRD2 A1 allele, and mutations in this gene have also been associated with schizophrenia and 14-16 alcoholism. Positron Emission Tomography (PET) studies showed that A1 allele is associated with lower DRD2 density,17 and reduction of glucose metabolism in dopaminergic human brain regions.18
The reward deficiency syndrome (RDS) is a hypo-dopaminergic state that predisposes to obsessive-compulsive and 2 19,20 impulsive behaviors. Obesity is part of RDS since the individual is predisposed to reward-driven eating behavior that leads to overeating as a way to compensate the defect in dopamine levels. All components of RDS, including obesity, were related to low dopaminergic function associated with the presence of the 13,19,20 DRD2 A1 allele. Thus, the aim of this study was to investigate the association between DRD2 gene Taq1A polymorphism and obesity, dyslipidemia and insulin resistance in children.
This study was conducted with 105 children and adolescents aged between 5 and 16 years (55 obese and 50 normalweight controls) that were evaluated by a pediatric endocrinologist at Children’s Hospital Goiânia. Exclusion criteria were: overweight, malnutrition, severe chronic diseases, presence of genetic syndromes, use of medications that can alter weight (glucocorticoids, growth hormone, insulin, Gonadotropin-releasing hormone-GnRH analogues, etc.).
Parents or guardians provided informed consent prior to participation in the study. Consent was approved by the Ethics Committee on Human Research at the Pontifical Catholic University of Goiás, under the protocol number 16303313.4.0000.0037. Parents or guardians answered a questionnaire focusing on lifestyle and habits of the child and family, the presence of obesity related diseases (diabetes mellitus, hypertension, dyslipidemia, myocardial infarction, and stroke), informed the height and maximum weight of each parents, excluding maternal pregnancy period, for calculation of maximum Body Mass Index (BMI) of parents.
The diagnosis of nutritional status was based on the BMI according to WHO.21 Anthropometric data (weight and height) were calculated based on the WHO Anthro Plus software (http://www.who.int/childgrowth/software/en/.48). Itran the BMI calculation in absolute number and in Z score according to age and sex of each child. We also evaluated metabolic measurements including lipid profile, fasting glucose and insulin. The
(HOMA-IR) and for beta cell function (HOMA ß) were calculated using traditional formulas HOMA-IR=(fasting insulin [μU/ ml] * fasting glucose [mmol/l]/22.5) and HOMA ß=(20*fasting insulin [μU/ml] * fasting glucose [mmol/l] – 3.5), the reference values are ≤3.4 and 167 to 175, respectively.22
Reference values for fasten glucose (mg/dl) do not differ between adults and children, being normal from 60 to 100, pre-diabetic between 101 and 125 and diabetic ≥126. Fasten insulinemia (UI/ml) is considered normal from 2,5 to 25 in adults and until 15 in children.23 Lipidogram was evaluated according to the I Brazilian Guidelines for Atherosclerosis Prevention in children and adolescents,24 as follows in Chart 1:
Desirable Frontier Elevated Lipid levels (mg/dl) (mg/dl) (mg/dl) Total Cholesterol (CT) <150 150-169 ≥170 Low-density lipoprotein(LDL-C) <100 100-129 ≥130 High-densitylipoprotein(HDL-C) ≥45 Triglycerides (TG) <100 100-129 ≥130
Figure 1. Referencesvalues for lipidlevels for chidrenfrom 2-19 year according to theI Brazil- ian Guidelines for Atherosclerosis Prevention in children and adolescents.
Genotyping was performed to identify the polymorphism Taq1A (C32806T or rs1800497) of DRD2. Biological samples were obtained by collecting 5 ml of peripheral blood in EDTA. Genomic DNA was isolated from whole blood using Illustra blood genomic Prep Mini Kit (GE Healthcare, United Kingdom) according to manufacturer’s instructions. DNA quantification was carried out using a NanoVue™ Plus spectrophotometer (GE Healthcare, United Kingdom) and stored in -20 °C until further processing.
To evaluate the DRD2 polymorphism we performed Restriction fragment length polymorphism system polymerase chain reaction (RFLP-PCR) according to Jönsson, et al. Amplification reactions were prepared to a final volume of 50 μL of solution containg approximately 100 ng of DNA. The reactions was prepared with 2 mM of MgCl2, 50 mM of KCl, 15 mM of Tris-HCl (pH 8.4), 10 pmol of primers, 0.2 mM of each dNTPs, and 1 U of Taq DNA polimerase (Promega Coorporation, EUA). The thermocycling protocol was: initial denaturation of 95 °C for 3 min followed by 30 cycles of denaturation at 95 °C for 30 seconds, annealing at 58 °C for 30 seconds and extension at 72 °C for 60 seconds, and the extension at 72 °C for 5 min. The sequence of the primers used in the RFLP-PCR reaction were MP3 primer (5’- ACCCTTCCTGAGTGTCATCA-3’) and MP4 primer (5’- ACGGCTGGCCAAGTTGTCTA-3’) producing an amplicom of 310 pb.
The restriction enzyme was carried out using a final volume of 25 μL, containing 8 μL of the PCR product, 2,5 μL of buffer, and 1 unit of the enzyme TaqIA. The solution remained for 1 hour at 65 °C in a water bath. The restriction resulted in two
fragments, one of 130 bp and another of 180 bp.
The amplicons and the restriction fragments were visualized by 1,5% agarose gel electrophoresis, submitted to an electric field of 10 V/cm, for one and a half hour. The PCR products were stained with ethidium bromide 0.5 mg/mL and documented ® using the Video Documentation System (VDS , Amersham Bioscience, EUA), connected to a microcomputer with a capture ® system and analysis of 21 images (Imagemaster , Amersham Bioscience, EUA).
Individuals with genotype A1/A1 (TT) do not have the site for the restriction enzyme TaqIA, therefore producing only undigested fragments of 310 pb. Individuals with genotypes A2/ A2 (CC) after the action of restriction enzyme TaqIA produce two fragments, 180 pb and 130 pb. Finally, individuals with heterozygous genotype A1/A2 (CT) show three fragments, 310 pb, 180 pb and 130 pb.
Metabolic measurements, HOMA IR, HOMA ß, parents BMI, and child Z-BMI were correlated with polymorphism using SPSS17 Statistics software. Data was analyzed with the X2 test, Odds Ratio (OR) and Analysis of variance (ANOVA). All tests were considered statistically significant at p≤0.05 with 95% of confidence interval.
™ Anthropometric and clinical analysis revealed 55(52,4%) obese and 50(47,6%) eutrophic children. In the first group, 28(50,9%) were female and 27(49,1%) were male, and in the second group 27(54%) were female and 23(46%) were male. Both groups were similar to age and gender. There were sig- 17 nificant differences (p≤0.05) between the two groups for weight, height, BMI-Z, parents BMI, insulin, HOMA-IR, HOMA- ß, and HDL-C (Table 1).
Genotypic distribution of DRD2 Taq1A (C32806T or rs1800497) was: 12,4% A1A1, 33,3% A1A2, and 54,3% A2A2. This distribution showed higher proportion to A1A1 and A1A2 in the obese group, and A2A2 in the eutrophic group, but this was not significantly different. Allelic distribution was significantly different (p=0.05) and there was a 1.3 RR for obesity in those who carried the A1 allele (Table 2).
Children were evaluated in groups according to the presence of allele A1, the A1A1+A1A2 group being the “risk genotype” and the A2A2 group providing the “no risk genotype”. This analysis showed statistical significance for weight, BMI-Z, mother BMI and TG (Table 3). The evaluation of genotypic distribution showed significant differences for BMI-Z, father BMI and TG (Table 4).
Age (Years) 9,6 1,8 Weight (kg) 56,6 15,6 Hight (cm) 142,5 10,2
Mother BMI (kg/m ) 29,2 5,3 Father BMI (kg/m2) 31,88 4,6 Fasten Glucose (mg/dl) 84,82 5,2 FastenInsulin (UI/ml) 12,44 5,8 Homa IR 2,64 1,3 Homa ß 212,23 96,5 TC (mg/dl) 167,05 24,3 HDL-C (mg/dl) 40,44 5,7 LDL-C (mg/dl) 109,62 20,9 TG (mg/dl) 86,73 31,0
BMI: Body Mass Index; Z BMI: Z score for BMI; HOMA: Homeostasis model assessment; IR: Insulin Resistance; ß: beta cell function; TC: Total Cholesterol; HDL-C: High-density lipoprotein; LDL-C: Low-density lipoprotein; TG: Triglycerides; SD: Standard Deviation.
Table 1. Anthropometric and clinical characteristics of obese and eutrophic groups.
RR: Relative Risk.
sistance; ß: beta cell function; TC: Total Cholesterol; HDL-C: High-density lipoprotein; LDL-C: Low-density lipoprotein; TG: Triglycerides; SD: Standard Deviation.
Table 3. Anthropometric and clinical characteristics in non-risk genotype group (A2A2).
10,2 2,3 0,194 30,2 7,6 <0,0001* 135,5 12,9 0,013* Z BMI 3,19 0,9 - 0,6 0,6 <0,0001* 23,46 2,6 <0,0001* 26,18 2,9 <0,0001* 86,02 5,7 0,362 6,37 2,4 <0,0001* 1,36 0,5 <0,0001* 107,34 43,7 <0,0001* 165,7 19,7 0,809 48,98 8,4 <0,0001* 101,2 18,4 0,101 80,06 29,4 0,388 Total 55(100) 50(100)
A1 38(34,5) 23(23) 1,2892 (0,05)* A2 72(65,5) 77(77) Total 110(100) 100(100)
Years (months) 119,6 29,85 118,3 31,24 0,823 Weight (Kg) 48,86 21,66 40,01 19,64 0,03* Hight (cm) 141,5 12,05 137,3 16,08 0,135 Z BMI 1,97 4,18 0,88 2,06 0,009*
Homa IR 2,19 1,48 1,89 1,68 0,33 Homa ß 182,19 121,49 145,51 103,96 0,098 TC (mg/dl) 161,1 26,2 170,88 29,8 0,08 HDL-C (mg/dl) 73,62 29,12 91,91 44,71 0,013* LDL-C (mg/dl) 44 7,98 44,93 11,13 0,63 TG (mg/dl) 102,79 23,65 107,98 28,25 0,315 Total 48(100) 57(100)
the observed risk genotype group (A1A1+A1A2) and
Mother BMI (kg/m ) 27,66 27,95 25,32 2,178 0,119 Father BMI (kg/m ) 33,29 28,65 28,58 3,385 0,038* Glucose (mg/dl) 84,92 85,43 85,47 0,036 0,965 Insulin (UI/ml) 11,2 10,08 8,85 0,715 0,491 HOMA IR 2,346 2,14 1,89 0,553 0,577 HOMA ß 201,96 174,85 145,51 1,659 0,195 TC (mg/dl) 153 164,11 170,88 2,308 0,105 HDL-C (mg/dl) 40,07 45,46 44,93 1,568 0,213 LDL-C (mg/dl) 97,15 104,89 107,98 0,919 0,402 TG (mg/dl) 82,84 70,2 91,91 3,471 0,035*
BMI: Body Mass Index; Z BMI: Z score for BMI; HOMA: Homeostasis model assessment; IR: Insulin Resistance; ß: beta cell function; TC: Total Cholesterol; HDL-C: High-density lipoprotein; LDL-C: Low-density lipoprotein; TG: Triglycerides; SD: Standard Deviation.
Table 4. Anthropometric and clinical characteristics observed in the genotype groups.
Allelic distribution was compared with groups classified according to the references values for normality of TC (<170 mg/dl-normal range or ≥170 mg/dl-elevated level)22 and HOMA ß (<175-normal or ≥175-altered). We observed significant difference for allelic distribution in children with TC<170 mg/dl or ≥170 mg/dl and in children with HOMA ß<175 or ≥175. The RR for A1 allele was 1.5 for HOMA ß≥175 (Tables 5 and 6). Associations between the A1 allele and TC ≥170 mg/dl and HOMA ß≥175 have not been described in the literature until now.
A1 16(19,5) 45(35,2) 0,0249* A2 66(80,5) 83(64,8) Total 82(100) 128(100)
Table 5. Allelic Distribution in the patients with TC<170 and TC≥170.
A1 35(24,6) 26(38,2) 1,5121 0,0367* A2 107(75,4) 42(61,8) Total 142(100) 68(100) RR: Relative Risk.
Table 6. Allelic Distribution in the patients with HOMA ß< 175 and HOMA ß≥175.
Children were divided in 4 subgroups in accordance to the function of pancreatic beta cells and BMI-Z: obese with normal HOMA ß (OßN), obese with altered HOMA ß (Oß↑), eutrophic with normal HOMA ß (EßN) and eutrophic with altered HOMA ß (Eß↑). Twenty six (47,3%) and 29(52,7%) obese children presented normal HOMA ß and altered HOMA ß, respectively. In the eutrophic group 45(90%) presented normal index and 5(10%) altered index. Allelic and genotypic distribution is shown in Tables 7, 8, 9 and 10. Subgroups with normal secreting pancreatic beta cell (OßN e EßN) demonstrated significant
Z BMI 1,948 1,977 0,88 3,470 0,035*
N (%) TOTAL 13(100) 35(100) 57(100)
ence of A1A1 and A1A2 genotypes and higher presence of A2 allele.
Genotype n(%) X² p n (%) X² p A1 A1 2(7,7) 6(20,7) A1 A2 11(42,3) 11(37,9) 7,923 0,019* 2,138 0,343 A2 A2 13(50) 12(41,4) Total 26(100) 29(100) TOTAL 55(100)
Table 7. Genotypic distribution in the obese subgroups with normal secreting pancreatic beta cells (OßN) and altered secreting pancreatic beta cells (Oß↑).
Geno - n(%) X² p n(%) X² p type A1 A1 4(8,9) 1(20) A1 A2 12(26,7) 1(20) 21,733 <0,0001* 1,6 0,449 A2 A2 29(64,4) 3(60) Total 45(100) 5(100) TOTAL 50(100)
Table 8. Genotypic distribution in the eutrophic subgroups with normal secreting pancreatic beta cells (EßN) and altered secreting pancreatic beta cells (Eß↑).
Allele n(%) X² p n (%) X² p A1 15(28,8) 23(39,7) 8,481 0,0036* A2 37(71,2) 35(60,3) 2,09 0,1486 TOTAL 52(100) 58(100)
Table 9. Allelic distribution in the obese subgroups with normal secreting pancreatic beta
Allele n(%) n(%) X² p A1 23(39,7) 20(22,2) A2 35(60,3) 70(77,8) 4,389 0,0362* Total 58(100) 90(100)
Table 10. Allelic distribution in the eutrophic subgroups with normal secreting pancreatic beta cells (EßN) and altered secreting pancreatic beta cells (Eß↑).
We compared allelic distribution between these 4 subgroups, and the groups Oß↑ and EßN were statistically different. Obese children with altered HOMA ß have a major presence of A1 allele (Table 11).
Allele n(%) n(%) X² p A1 23(39,7) 20(22,2) A2 35(60,3) 70(77,8) 4,389 0,0362* Total 58(100) 90(100)
Table 11. Comparison of allelic distribution in the Oß↑ e EßN subgroups.
Anthropometric and clinical analysis revealed some differences between the obese and eutrophic groups. The significant difference in weight and BMI-Z is expected and is itself the definition of each group. The greater height observed in the obese group is in accordance with usual clinical findings in this group of children, and is confirmed by clinical studies showing that obese children are taller than their peers of same age. However, since they have accelerated bone maturation, their growth occurs for a shorter period of time, not leading to changes in final adult height.25
The presence of higher levels of parents BMI of obese children corroborates studies that indicate a strong genetic com- 26-28 ponent in human obesity. The cchildren in the present study coexist in the same environment as their biological family (except for two), and therefore are exposed to the same lifestyle. It’s known that a child who has both obese parents has 80% chance of being obese, 50% if one parentis obese, and 9% when both parents are not obese.29 In our study, the mean BMI of parents is above normal in both groups. The eutrophic children group had overweight parents, consistent with the increase of overweight and obesity in the adult Brazilian population, reaching 48% of women and 50% of men.
In this study, obese and eutrophic groups presented the same level of blood glucose, however, obese group showed higher levels of insulin, HOMA IR and HOMA ß. These changes in insulin sensitivity and pancreatic beta cell secretion are related to obesity, which is an important risk factor for the development of Type 2 Diabetes Mellitus (DM2).4 The finding of lower level of HDL-C in the obese group is expected, since the presence of risk factors for cardiovascular disease in obese children is com- 4,5 mon.4,5
The TaqIA polymorphism (C32806T) of DRD2 gene is associated with decreased brain dopaminergic activity,31 and the 20,32 A1 allele was related with increased BMI in adults. Few studies have been conducted to verify the association of the DRD2 polymorphism TaqIA in children and adolescents.
In this study, we identified 34,5% and 23% for A1 allele in obese and eutrophic groups respectively, and a statistically significant association between the presence of A1 allele with childhood obesity conferringa relative risk of 1,3. Studies noted a wide variation in allele frequencies, even within the same country populations. In two studies conducted with Turkish children, one of them showed 51% of the A1 allele in obese,34 while another reported only 20%. A Dutch study showed the frequency of 18.3% of A1 allele35 and in North American studies the frequency of the A1 allele in obese children ranged from 36 37 17%36 to 38.5%.37
The DRD2 TaqIA polymorphism was previously evaluated in children and/or adolescents among few other groups. The A1 allele was associated with obesity in one study,37 other 23,34 2 studies did not find this association; it was also described compulsive feeding behavior35 and difficulties in acceptance for healthier life style modification.36
Although TG levels were lower in the A1 allele group, this difference was not clinically relevant, since all groups showed TG in the normal range. TG levels were 20% lower in the “risk genotype” group as compared with “no risk genotype” group and was 10% lower in subjects with A1A1 genotype compared with A2A2 genotype group. Miyashita and colleagues performed a meta-analysis evaluating the effect of physical exercise on TG levels and found significant decreases in TG after short time and intermittent physical exercise. The decrease in TG levels ranged from 10% to five minutes practice of exercise six times per day, up to 27% for practice of 10 minutes 3 times per day.38 It was hypothesized that children with the presence of the A1 allele have the lowest TG, due to higher levels of physical activity. The presence of A1 allele contributes to the Reward Deficiency Syndrome (RDS), in which Attention Deficit/Hyperactivity Disorder (ADHD) is part,20 moreover studies assessing the Taq IA polymorphism of DRD2 gene and personality traits using the Tridimensional Personality Questionnaire demonstrate that A1 allele is associated with certain behavioral traits, with 39-42 higher levels of impulsivity, extravagance, disorganization, 39-41 40-42 persistence and gregarious attitude. These behavioral characteristics may lead to greater practice of physical exercise by the children with the A1 allele, and thus may explain lower TG levels.
The association of A1 allele with higher frequency of CT≥170 mg/dl is explained by the feeding behavior assigned to A1 allele carriers as a way to compensate for the RDS.
Our study demonstrated the association of impaired
function of pancreatic beta cells with A1 allele conferring a relative risk of 1.5 for HOMA ß≥175. Clinical studies in diabetic 43 44 patients43 and in animal studies44 show improvement of glucose control with the use of bromocriptine, a dopamine agonist which acts throw DRD2 receptors. In 2005, Ruby and colleagues first demonstrated that DRD2 receptors are expressed in pancreatic beta cells and modulate the secretion of insulin.45 Study conducted in rats “knockout” for the DRD2 gene revealed that DRD2 receptors play a crucial role in insulin secretion and glucose homeostasis; mice with absence of the DRD2 receptor had a flat insulin response to glucose load, higher fasting glucose, impaired glucose tolerance and decreased beta cell mass. These results indicate that DRD2 is important for beta cell proliferation and insulin secretion, and may be considered as a growth factor essential for the control of glucose homeostasis.
For the first time, the A1 allele of the DRD2 gene is associated with alteration of glucose homeostasis in humans. The presence of this allele reduces the number of brain receptors; it is assumed that must also reduce the number of receptors on beta cells, explaining our clinical findings. The presence of the A2 allele was associated with normal HOMA ß in eutrophic and obese patients, demonstrating a protective effect of this allele in the pancreatic secretion.
Regarding the TaqIA (C32806T) polymorphism of DRD2 gene we observed several statistically significant results. A1 allele (T) is associated with: higher weight and children Z- BMI, conferring a relative risk of 1.3 for the presence of childhood obesity. This allele is also associated with higher BMI of the mother and father. Regarding the lipid profile, the A1alleleis associated with lower levels of TG and higher frequency of CT≥170 mg/dl.
With respect to carbohydrate metabolism, our study found an unprecedented result in the literature: the A1 allele was associated with HOMA ß≥175, giving a relative risk of 1.5. The A2 allele was associated with normal HOMA ß in obese and eutrophic individuals, demonstrating the involvement of this allele as a protective factor for pancreatic secretion.
The major limitation of this study is the relatively small population. Even though, our research opens a new line of investigation: the relationship between early-onset obesity, the TaqIA polymorphism of the DRD2 gene and abnormality of secretion of pancreatic beta cells
Despite widely recognized that genetic factors are important for weight gain, the actual quantitative contribution of genetics in related phenotypes is still a complex issue that needs to be clarified. The knowledge of the genetic architecture of obesity will increase our understanding of the regulation of
the treatment and prevention of this serious health problem. The recognition of predisposed individuals by determining risk polymorphisms can establish new pathways for the treatment and prevention of childhood obesity. We believe that in the future children will be treated based on their genomes.
The authors declare that they have no conflicts of interest.
We would like to thank all participating subjects and families. 46 This research was financially supported by the Núcleo de Pesquisas Replicon, Departamet of Biology, Pontifícia Universidade Católica de Goiás, Goiânia, Goiás, Brazil.